美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Therapeutics

4.14

-0.0900-2.13%

盤後：4.13-0.0100-0.24%16:58 EDT

成交量：75.85萬

成交額：316.94萬

市值：1.30億

市盈率：-1.00

高：4.29

開：4.23

低：4.12

收：4.23

52周最高：50.40

52周最低：4.12

股本：3,129.00萬

流通股本：1,839.33萬

量比：0.99

換手率：4.12%

股息：- -

股息率：- -

每股收益(TTM):-4.1300

每股收益(LYR):-2.8503

淨資產收益率：-59.21%

總資產收益率：-37.36%

市淨率：0.59

市盈率(LYR):-1.45

資料載入中...

總覽公司新聞資訊公告

BMS多發性骨髓瘤III期數據亮眼 C4 Therapeutics受提振大漲

环球市场播报

Aldeyra Therapeutics投資者迎來集體訴訟主導權申請截止日

环球市场播报

Atossa Therapeutics在ASCO 2026公布(Z)-Endoxifen積極數據，展現克服ESR1突變潛力

环球市场播报

Turn Therapeutics發表GX-03抗炎新數據，助力皮膚病精準治療

环球市场播报

臨床階段RNAi療法公司Silence Therapeutics將出席Jefferies全球醫療保健年會

环球市场播报

Indaptus Therapeutics Q1淨虧損收窄，現金儲備大幅下降

环球市场播报

Atrium Therapeutics Q1淨虧損1660萬美元，BMS里程碑付款支撐收入

环球市场播报

Aptevo Therapeutics公布一季度業績及臨床進展

环球市场播报

美國研究綜述-Accuray、Aevex、Zoetis

Piper Sandler下調Lenz Therapeutics評級至中性，目標價大幅削減至12美元

美股異動 | Odyssey Therapeutics(ODTX.US)登陸美股市場開盤股價波動不大

Atossa Therapeutics一季度GAAP每股虧損1.11美元

环球市场播报

拜耳斥資24.5億美元收購Perfuse Therapeutics

环球市场播报

Axsome Therapeutics Inc(AXSM)股票5月4日盤中上漲10.20%：背後推手曝光

TradingKey中文

億騰嘉和(06998)：Candid Therapeutics被UCB收購首付款20億美元

LENZ Therapeutics將於2026年5月11日公布第一季度財報並參與投資者會議

Avalo Therapeutics達成里程碑付款買斷協議優化資本結構

美國FDA拒絕批准Grace Therapeutics腦卒中藥物

环球市场播报

Trevi Therapeutics完成1.73億美元承銷發行承銷商全額行使超額配售權

Lenz Therapeutics向英國藥監局提交Vizz®老花眼治療藥物上市許可申請

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/LENZ/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":4.14,"timestamp":1789588800000,"preClose":4.23,"halted":0,"volume":758477,"hourTrading":{"tag":"盘后","latestPrice":4.13,"preClose":4.14,"latestTime":"16:58 EDT","volume":5598,"amount":23173.5434976,"timestamp":1789592321971,"change":-0.01,"changeRate":-0.002415,"amplitude":0.004831},"delay":0,"changeRate":-0.021276595744681024,"floatShares":18393300,"shares":31289969,"eps":-4.13,"marketStatus":"盤後交易","change":-0.09,"latestTime":"09-16 17:02:48 EDT","open":4.23,"high":4.285,"low":4.12,"amount":3169370.7786368,"amplitude":0.039007,"askPrice":4.17,"askSize":27,"bidPrice":4.13,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-4.13,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":4.23,"preHourTrading":{"tag":"盘前","latestPrice":4.2048,"preClose":4.23,"latestTime":"09:25 EDT","volume":813,"amount":3427.8884849999995,"timestamp":1789565102395,"change":-0.0252,"changeRate":-0.005957,"amplitude":0.034326},"postHourTrading":{"tag":"盘后","latestPrice":4.13,"preClose":4.14,"latestTime":"16:58 EDT","volume":5598,"amount":23173.5434976,"timestamp":1789592321971,"change":-0.01,"changeRate":-0.002415,"amplitude":0.004831},"volumeRatio":0.993503,"impliedVol":2.5034,"impliedVolPercentile":0.8845},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":18393300,"roa":"-37.36%","roe":"-59.21%","lyrEps":-2.850329,"volumeRatio":0.993503,"shares":31289969,"dividePrice":0,"high":4.285,"amplitude":0.039007,"preClose":4.23,"low":4.12,"week52Low":4.12,"pbRate":"0.59","psRate":"6.03","week52High":50.4,"institutionHeld":0,"latestPrice":4.14,"committee":-0.928571,"eps":-4.13,"divideRate":0,"volume":758477,"delay":0,"ttmEps":-4.13,"open":4.23,"prevYearClose":16,"prevWeekClose":4.52,"prevMonthClose":5.21,"prevQuarterClose":5.68,"fiveDayClose":4.91,"twentyDayClose":4.77,"sixtyDayClose":5.82},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"LENZ","fiscalQuarterEnding":"2026/06","expectedEps":-1.21,"name":null,"time":"盤後","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-1.02},{"market":"US","date":"2026-05-11","symbol":"LENZ","fiscalQuarterEnding":"2026/03","expectedEps":-1.1,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-03-24","symbol":"LENZ","fiscalQuarterEnding":"2025/12","expectedEps":-0.91,"name":null,"time":"盤前","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"盤前","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.2857,"hold":0.2857,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2857,"analysts":7,"updateTime":1786593600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-09-15","current":-1.016949,"percent":1,"low":-26.69966,"twenty":-16.219821,"median":-9.723534,"eighty":-5.168633,"high":-1.114656,"avg":-10.473331,"sd":6.21597,"marketCap":140448933},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380},{"date":"2026-03-06","current":-6.40859,"twenty":-17.073997,"median":-11.306259,"eighty":-7.995871,"marketCap":377357026},{"date":"2026-03-13","current":-6.281056,"twenty":-17.036729,"median":-11.290275,"eighty":-7.848663,"marketCap":369847433},{"date":"2026-03-20","current":-6.105697,"twenty":-16.999628,"median":-11.252126,"eighty":-7.671592,"marketCap":359521743},{"date":"2026-03-27","current":-3.413108,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"marketCap":280308282},{"date":"2026-04-02","current":-3.569637,"twenty":-16.958959,"median":-11.220775,"eighty":-7.447644,"marketCap":293163583},{"date":"2026-04-10","current":-3.54673,"twenty":-16.933679,"median":-11.193196,"eighty":-7.269441,"marketCap":291282320},{"date":"2026-04-17","current":-3.680353,"twenty":-16.916201,"median":-11.141188,"eighty":-7.181235,"marketCap":302256358},{"date":"2026-04-24","current":-3.493281,"twenty":-16.878888,"median":-11.077981,"eighty":-6.952736,"marketCap":286892705},{"date":"2026-05-01","current":-3.428379,"twenty":-16.817122,"median":-11.044571,"eighty":-6.825202,"marketCap":281562458},{"date":"2026-05-08","current":-3.710895,"twenty":-16.761494,"median":-10.861657,"eighty":-6.578636,"marketCap":304764709},{"date":"2026-05-15","current":-2.097082,"twenty":-16.730518,"median":-10.778852,"eighty":-6.457565,"marketCap":228573532},{"date":"2026-05-22","current":-2.163245,"twenty":-16.709792,"median":-10.723495,"eighty":-6.429023,"marketCap":235785042},{"date":"2026-05-29","current":-2.298448,"twenty":-16.694346,"median":-10.694071,"eighty":-6.404339,"marketCap":250521608},{"date":"2026-06-05","current":-2.071192,"twenty":-16.632408,"median":-10.560046,"eighty":-6.370576,"marketCap":225751636},{"date":"2026-06-12","current":-1.869826,"twenty":-16.608825,"median":-10.439663,"eighty":-6.329861,"marketCap":203803561},{"date":"2026-06-18","current":-1.8238,"twenty":-16.599392,"median":-10.388191,"eighty":-6.238545,"marketCap":198786857},{"date":"2026-06-26","current":-1.585037,"twenty":-16.591349,"median":-10.356288,"eighty":-6.201347,"marketCap":172762710},{"date":"2026-07-02","current":-1.665584,"twenty":-16.562409,"median":-10.323331,"eighty":-6.136275,"marketCap":181541941},{"date":"2026-07-10","current":-1.665584,"twenty":-16.458857,"median":-10.297741,"eighty":-6.098214,"marketCap":181541941},{"date":"2026-07-17","current":-1.403808,"twenty":-16.42504,"median":-10.207556,"eighty":-5.994366,"marketCap":153009442},{"date":"2026-07-24","current":-1.452711,"twenty":-16.399781,"median":-10.175633,"eighty":-5.904593,"marketCap":158339689},{"date":"2026-07-31","current":-1.656954,"twenty":-16.359791,"median":-10.130408,"eighty":-5.831073,"marketCap":180601309},{"date":"2026-08-07","current":-1.501614,"twenty":-16.336075,"median":-10.052902,"eighty":-5.780516,"marketCap":163669936},{"date":"2026-08-14","current":-1.147074,"twenty":-16.332656,"median":-9.910465,"eighty":-5.64279,"marketCap":144533577},{"date":"2026-08-21","current":-1.162036,"twenty":-16.31728,"median":-9.875604,"eighty":-5.484249,"marketCap":146418798},{"date":"2026-08-28","current":-1.19944,"twenty":-16.297238,"median":-9.783769,"eighty":-5.425546,"marketCap":151131849},{"date":"2026-09-04","current":-1.453791,"twenty":-16.251993,"median":-9.763078,"eighty":-5.336455,"marketCap":183180599},{"date":"2026-09-11","current":-1.176997,"twenty":-16.223282,"median":-9.734689,"eighty":-5.236314,"marketCap":148304018},{"date":"2026-09-15","current":-1.114656,"twenty":-16.219821,"median":-9.723534,"eighty":-5.168633,"marketCap":140448933}],"updateTime":1789567666488},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2639725276","title":"BMS多發性骨髓瘤III期數據亮眼 C4 Therapeutics受提振大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2639725276","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639725276?lang=zh_tw&edition=fundamental","pubTime":"2026-05-30 03:49","pubTimestamp":1780084140,"startTime":"0","endTime":"0","summary":"百时美施贵宝日前公布了其在研药物美齐格米德的III期临床试验阳性数据。结果显示，该联合疗法将复发或难治性多发性骨髓瘤患者的疾病进展或死亡风险降低了52%。这一积极结果不仅推高了施贵宝的股价，也显著提振了同领域生物科技公司C4 Therapeutics的市场表现。　　在施贵宝宣布这一消息后，C4 Therapeutics股价应声大涨，盘中一度触及52周新高，最终收涨逾19%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-30/doc-inhzrera0552232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","BK4134","III","LENZ","BK4539","CCCC","BMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639675738","title":"Aldeyra Therapeutics投資者迎來集體訴訟主導權申請截止日","url":"https://stock-news.laohu8.com/highlight/detail?id=2639675738","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639675738?lang=zh_tw&edition=fundamental","pubTime":"2026-05-29 22:54","pubTimestamp":1780066440,"startTime":"0","endTime":"0","summary":"生物制药公司Aldeyra Therapeutics近日面临证券欺诈集体诉讼，多家律所提醒投资者，申请担任首席原告的截止日期为2026年5月29日。　　此次诉讼源于美国食品药品监督管理局于2026年3月17日对该公司的干眼症候选药物reproxalap新药申请发出完全回复函，正式拒绝批准。　　诉讼指控在2023年11月3日至2026年3月16日期间，Aldeyra及其部分高管违反了联邦证券法，就reproxalap临床试验结果作出了虚假和误导性陈述，未能披露试验数据的不一致性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-29/doc-inhzqtze7774976.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638763334","title":"Atossa Therapeutics在ASCO 2026公布(Z)-Endoxifen積極數據，展現克服ESR1突變潛力","url":"https://stock-news.laohu8.com/highlight/detail?id=2638763334","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638763334?lang=zh_tw&edition=fundamental","pubTime":"2026-05-28 03:13","pubTimestamp":1779909180,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Atossa Therapeutics， Inc．今日宣布，两篇关于其在研药物-Endoxifen的摘要已获2026年美国临床肿瘤学会年会收录，该年会将于5月29日至6月2日在芝加哥举行。摘要重点展示了该药物在携带ESR1突变的乳腺癌模型中的抑制活性，以及正在进行的EVANGELINE二期临床试验的最新进展。与口服选择性雌激素受体降解剂elacestrant及imlunestrant相比，-Endoxifen在ESR1突变环境中显示出更优的抑制效果。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-28/doc-inhzksky8044604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK4551","BK4585","BK4588","BK4539","BK4007","BK4548","BK4079","LENZ","Z"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638684358","title":"Turn Therapeutics發表GX-03抗炎新數據，助力皮膚病精準治療","url":"https://stock-news.laohu8.com/highlight/detail?id=2638684358","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638684358?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 23:35","pubTimestamp":1779896100,"startTime":"0","endTime":"0","summary":"Turn Therapeutics近日宣布，一篇关于其先导候选药物GX-03在IL-36相关炎症模型中活性的同行评审研究论文，已发表于《皮肤病学治疗杂志》。该研究为GX-03治疗中重度特应性皮炎的作用机制提供了新的科学依据，标志着公司对炎症性皮肤病局部治疗研究方法的转变。就在上月，Turn Therapeutics还与Avenue Capital Group旗下基金达成了一项最高2500万美元的成长资本贷款协议，首笔700万美元已到账，将用于支持GX-03项目的推进并可能将现金跑道延续至2期数据公布之后。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-27/doc-inhzkfvc1468955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","BK4539","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638896436","title":"臨床階段RNAi療法公司Silence Therapeutics將出席Jefferies全球醫療保健年會","url":"https://stock-news.laohu8.com/highlight/detail?id=2638896436","media":"环球市场播报","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638896436?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 22:37","pubTimestamp":1779892620,"startTime":"0","endTime":"0","summary":"临床阶段RNAi疗法公司Silence Therapeutics近日宣布，公司管理层将出席2026年6月3日下午4：55举行的Jefferies全球医疗保健年会，并进行分析师主导的炉边谈话。投资者可通过公司官网投资者关系页面收听现场网络直播，回放将在会议结束后提供。　　Silence Therapeutics目前最受关注的资产是divesiran，一种靶向TMPRSS6的siRNA疗法，用于治疗真性红细胞增多症。　　Silence Therapeutics总部位于伦敦，在纳斯达克以“SLN”代码交易，员工约88人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-27/doc-inhzkfvc1451718.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","XLV","VHT","BK4585","LABU","LENZ","BK4550","XBI","BK4581","BK4539","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635035245","title":"Indaptus Therapeutics Q1淨虧損收窄，現金儲備大幅下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035245","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635035245?lang=zh_tw&edition=fundamental","pubTime":"2026-05-15 23:46","pubTimestamp":1778859960,"startTime":"0","endTime":"0","summary":"　　Indaptus Therapeutics公布2026年第一季度财报。公司报告期内净亏损为254万美元，合每股亏损0.23美元，较上年同期的453万美元亏损和每股亏损9.11美元显著收窄。每股亏损的大幅减少主要源于2025年6月实施的1比28反向股票分割带来的股份数量增加。一般及行政费用为167万美元，同比略有下降。　　截至季末，公司现金及现金等价物仅为150万美元，较2025年末的850万美元大幅下降。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-15/doc-inhxyyie6357238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LENZ","BK4539","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635035758","title":"Atrium Therapeutics Q1淨虧損1660萬美元，BMS里程碑付款支撐收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035758","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635035758?lang=zh_tw&edition=fundamental","pubTime":"2026-05-15 23:41","pubTimestamp":1778859660,"startTime":"0","endTime":"0","summary":"　　Atrium Therapeutics公布2026年第一季度财报。公司报告期内净亏损为1663万美元，合每股亏损0.97美元。作为对比，公司在作为Avidity Biosciences子公司期间的2025年同期净亏损为745万美元，合每股亏损0.44美元。需要说明的是，由于Atrium于2026年2月27日才完成从Avidity的分拆独立上市，本期财务数据不宜直接与历史同期进行比较。　　Atrium于2月27日正式作为独立公司登陆纳斯达克。ATR 1072的IND申请预计于2026年下半年提交，ATR 1086的IND申请预计于2027年提交。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-15/doc-inhxyyie6355365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","IE0009354923.USD","BK4585","BK4539","BMS","LENZ","BK4505","BK4139","BK4588","RNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635359547","title":"Aptevo Therapeutics公布一季度業績及臨床進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2635359547","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635359547?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 22:49","pubTimestamp":1778683740,"startTime":"0","endTime":"0","summary":"临床阶段生物技术公司Aptevo Therapeutics周三发布2026年第一季度业务更新，披露现金储备及核心管线试验的最新进展。公司同步宣布完成管理层交接。　　截至2026年3月31日，Aptevo持有现金及现金等价物1450万美元。　　公司同步宣布完成管理层过渡，新任命的首席执行官表示，核心药物持续产生令人信服的一线数据，将强效缓解活性与差异化的安全性特征相结合，有潜力成为标准疗法的重要补充。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-13/doc-inhxunaz7338741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","BK4539","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634298470","title":"美國研究綜述-Accuray、Aevex、Zoetis","url":"https://stock-news.laohu8.com/highlight/detail?id=2634298470","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634298470?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 15:22","pubTimestamp":1778570557,"startTime":"0","endTime":"0","summary":"美国研究综述-Accuray、Aevex、Zoetis路透5月12日 - 周二，华尔街的证券分析师们下调了多家在美国上市公司的评级和目标股价，其中包括Accuray、Aevex和Zoetis。股票按字母顺序排列。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL4T41P0LY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIYY","VSNT","TGT","BN","AVEX","LU1244550221.USD","HMYY","PLNT","VCTR","000338","CVS","LQDA","AMAT","SNDA","SIBN","ARAY","WPC","MOS","CGNX","ALMR","TXG","GTM","BX","HIMZ","SGI","IE00BFXG1179.USD","ASTH","CEVA","ZTS","SPG","BAM","LENZ","HIMS","HIMY","BK4585","PSIX","AGM","APO","KKR","LU1496350171.SGD","FTV","SKYE","TOST","TRGP","CYTK","ARES","CE","ELVN","LU2023250504.SGD","BILL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109919604","title":"Piper Sandler下調Lenz Therapeutics評級至中性，目標價大幅削減至12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1109919604","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109919604?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 10:34","pubTimestamp":1778553253,"startTime":"0","endTime":"0","summary":"投资银行Piper Sandler宣布，将生物技术公司Lenz Therapeutics的股票评级从“增持”下调至“中性”。与此同时，该机构大幅调降了对该公司的目标股价，从此前的39美元大幅削减至12美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634465519","title":"美股異動 | Odyssey Therapeutics(ODTX.US)登陸美股市場 開盤股價波動不大","url":"https://stock-news.laohu8.com/highlight/detail?id=2634465519","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634465519?lang=zh_tw&edition=fundamental","pubTime":"2026-05-09 00:00","pubTimestamp":1778256000,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，Odyssey Therapeutics(ODTX.US)登陆美股市场，开盘股价波动不大，IPO价格为18美元。截至发稿，该股跌超1%，报17.81美元。Odyssey Therapeutics是一家总部位于美国波士顿的临床阶段生物科技公司，主要专注于自身免疫性及炎症性疾病药物研发。公司核心产品为OD-001，这是一款用于治疗溃疡性结肠炎的小分子药物，目前已进入中期临床试验阶段。此外，公司还布局红斑狼疮、特应性皮炎等多个免疫疾病管线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LENZ","BK4139","BK4007","ODTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633450362","title":"Atossa Therapeutics一季度GAAP每股虧損1.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2633450362","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633450362?lang=zh_tw&edition=fundamental","pubTime":"2026-05-08 22:49","pubTimestamp":1778251740,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Atossa Therapeutics公布2026年第一季度财报，GAAP每股亏损1.11美元。由于公司尚无商业化产品，本季度未录得营收。　　财报显示，公司一季度净亏损约1.38亿美元，较上年同期净亏损650万美元大幅扩大。剔除一次性项目后，调整后每股亏损约为0.18美元。截至3月31日，公司持有现金及短期投资约1.15亿美元，较年初减少约2000万美元。　　财报发布后，Atossa股价在盘后交易中下跌约5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-08/doc-inhxfamz4272189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK4007","UDN","BK4539","LENZ","UUP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633902722","title":"拜耳斥資24.5億美元收購Perfuse Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2633902722","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633902722?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 16:02","pubTimestamp":1778054520,"startTime":"0","endTime":"0","summary":"德国拜耳公司周三宣布，将收购生物制药公司Perfuse Therapeutics，以完善其眼科产品线。\n　　拜耳在一份声明中表示，该交易潜在价值高达24.5亿美元，其中包括3亿美元的首付款，以及根据研发、监管和商业里程碑进展情况支付的额外款项。\n　　该交易将使拜耳获得PER-001的全部权益。PER-001是一种小分子内皮素受体拮抗剂（ERA），目前正处于II期临床开发阶段，用于治疗青光眼和糖尿病视网膜病变。\n　　拜耳表示，此次收购将在获得必要的反垄断审批和Perfuse股东批准后生效。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：于健 SF069","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-06/doc-inhwxxki3422808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4539","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633496815","title":"Axsome Therapeutics Inc(AXSM)股票5月4日盤中上漲10.20%：背後推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2633496815","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633496815?lang=zh_tw&edition=fundamental","pubTime":"2026-05-05 03:17","pubTimestamp":1777922226,"startTime":"0","endTime":"0","summary":"• FDA批准Auvelity用于治疗阿尔茨海默症激越。\n• 2026财年第一季度营收同比增长57%。\n• 分析师维持积极评级并上调目标价。","market":"fut","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/261853819-market-movers-axsm-20260504","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4505","BK4139","BK4585","BK4539","BK4007","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632511159","title":"億騰嘉和(06998)：Candid Therapeutics被UCB收購 首付款20億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2632511159","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632511159?lang=zh_tw&edition=fundamental","pubTime":"2026-05-04 22:51","pubTimestamp":1777906296,"startTime":"0","endTime":"0","summary":"于2024年9月，Candid Therapeutics, Inc.与TRC 2004, Inc.合并。集团与Candid Therapeutics订立了日期为2025年3月28日的修订协议，以修订及补充许可协议的若干条款，共同推动GB261在自身免疫领域的临床开发。于2026年5月3日，于布鲁塞尔泛欧交易所上市的比利时医药集团Union Chimique Belge宣布已签署一项最终协议，据此其将收购 Candid Therapeutics。根据协议条款，UCB须支付首付款20亿美元，连同高达2亿美元的潜在未来里程碑付款，惟须视乎是否达成指定里程碑而定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4539","BK4007","BK1583","BK4211","UCB","BK1161","LENZ","BK1574","06998"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1107930113","title":"LENZ Therapeutics將於2026年5月11日公布第一季度財報並參與投資者會議","url":"https://stock-news.laohu8.com/highlight/detail?id=1107930113","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107930113?lang=zh_tw&edition=fundamental","pubTime":"2026-05-04 20:02","pubTimestamp":1777896178,"startTime":"0","endTime":"0","summary":"圣地亚哥，2026年5月4日——专注商业化VIZZ1.44%的制药企业LENZ Therapeutics宣布，将于2026年5月11日东部时间下午4:30举行网络直播，披露2026年第一季度财务业绩及近期公司动态。该产品是全球首个且唯一获FDA批准的醋克利定滴眼液，用于治疗成人老花眼。直播链接亦可在LENZ Therapeutics官网的\"投资者与媒体\"专区获取。此外，公司管理层将于2026年5月13日至14日出席在拉斯维加斯举行的美国银行全球医疗健康大会，并安排一对一会议。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4007","LENZ","R","BK4139","BK4539","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136316695","title":"Avalo Therapeutics達成里程碑付款買斷協議 優化資本結構","url":"https://stock-news.laohu8.com/highlight/detail?id=1136316695","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136316695?lang=zh_tw&edition=fundamental","pubTime":"2026-04-28 19:15","pubTimestamp":1777374917,"startTime":"0","endTime":"0","summary":"临床阶段生物技术公司Avalo Therapeutics Inc  近日宣布，就2024年3月收购AlmataBio公司所涉条款达成里程碑付款买断协议。通过该选择权，Avalo可选择以现金、普通股或组合形式支付512.5万美元，替代原定在III期临床试验首例患者给药时需支付的1500万美元或有里程碑款项。通过前置部分付款义务，Avalo在保留研发推进主动权的同时，有效规避了未来可能产生的高额里程碑付款风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","AVTX","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629852486","title":"美國FDA拒絕批准Grace Therapeutics腦卒中藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2629852486","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629852486?lang=zh_tw&edition=fundamental","pubTime":"2026-04-24 02:43","pubTimestamp":1776969780,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局近日已向Grace Therapeutics发出完整回应函，拒绝批准其候选药物治疗特定类型脑卒中（中风）的上市申请。FDA在函件中指出，根据现有数据，暂无法确认该药物的临床获益大于风险，并要求公司在药品获批前补充相关的临床试验数据或生产质量控制信息。　　Grace Therapeutics方面随即回应称，正对FDA的反馈进行详细评估。　　此次拒绝为该公司的新药上市之路增加了新的不确定性，至于Grace是选择提起上诉还是重新提交申请，还有待公司进一步披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-24/doc-inhvpqks5066320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","BK4585","BK4539","LENZ","BK4139","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115266921","title":"Trevi Therapeutics完成1.73億美元承銷發行 承銷商全額行使超額配售權","url":"https://stock-news.laohu8.com/highlight/detail?id=1115266921","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115266921?lang=zh_tw&edition=fundamental","pubTime":"2026-04-21 04:08","pubTimestamp":1776715692,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Trevi Therapeutics近日宣布，其此前公布的承销公开发行已正式完成。本次发行以每股13.00美元的价格公开发行13,340,000股普通股，其中包括承销商全额行使期权，以发行价额外购买的1,740,000股普通股。在扣除承销折扣和佣金前，本次发行总收益约为1.73亿美元。所有发行股份均由Trevi公司售出。Trevi拟将Haduvio作为口服纳布啡缓释片的商品名。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225283273.USD","LU2347655156.SGD","LU2028103732.USD","BK4585","LU0158827781.USD","LU0098860793.USD","BK4555","IE00BZ1G4Q59.USD","LU0106261372.USD","LU2023251221.USD","LU2357305700.SGD","LU2133065610.SGD","MS","LU1720051017.SGD","LU2089283258.USD","LU0882574139.USD","LU0557290698.USD","LU0795875086.SGD","BK4099","LU1363072403.SGD","LU0912757837.SGD","LU0320765646.SGD","LU1244550221.USD","LU2089284900.SGD","LU1791710400.SGD","LU0795875169.SGD","BK4588","LU1720051108.HKD","LU0528227936.USD","LENZ","LU0314104364.USD","BK4516","BK4581","LU0006306889.USD","TRVI","LU1791710582.SGD","IE00BKVL7J92.USD","LU0158827948.USD","LU2111349929.HKD","TM","LU1162221912.USD","RCC","BK4534","LU1548497426.USD","03160","LU0971096721.USD","BK4504","LU1074936037.SGD","LU1244550494.USD","BK4007","BK4127","BK4604","LU1668664300.SGD","LU2271345857.HKD","LU0234570918.USD","LU1989772923.USD","BK4139","LU1989772840.SGD","LU1732799900.SGD","LU0106831901.USD","LU1732800096.USD","BK4539","LU0267386448.USD","LU1244550577.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126480925","title":"Lenz Therapeutics向英國藥監局提交Vizz®老花眼治療藥物上市許可申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1126480925","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126480925?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 20:00","pubTimestamp":1776686431,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics公司已正式向英国药品和保健品监管局提交了Vizz®药物的上市许可申请，该药物主要用于治疗老花眼。此次申请标志着该疗法在英国市场商业化进程的重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":92,"code":"91000000","status":"200"}]}}